Beyond PD-L1: Challenges in Implementing Tumor Mutational Burden (TMB) to Predict Patient Response to Immuno-Oncology (IO) Therapies

被引：0
|
作者：
Krein, P. M. [1 ]
机构：
[1] Diaceutics Inc, Parsippany, NJ USA
来源：
JOURNAL OF MOLECULAR DIAGNOSTICS | 2017年 / 19卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
ST129
引用
收藏
页码：1039 / 1039
页数：1
相关论文
共 50 条
  • [1] PD-L1 and beyond: Immuno-oncology in cytopathology
    Iaccarino, Antonino
    Salatiello, Maria
    Migliatico, Ilaria
    De Luca, Caterina
    Gragnano, Gianluca
    Russo, Maria
    Bellevicine, Claudio
    Malapelle, Umberto
    Troncone, Giancarlo
    Vigliar, Elena
    CYTOPATHOLOGY, 2021, 32 (05) : 596 - 603
  • [2] Tumor mutational burden (TMB) and PD-L1 expression as predictors of response to immunotherapy (IO) in NSCLC.
    Castellanos, Emily
    Snider, Jeremy
    Ali, Siraj Mahamed
    Backenroth, Daniel
    Albacker, Lee A.
    Murugesan, Karthikeyan
    Li, Gerald
    Frampton, Garrett M.
    Alexander, Brian Michael
    Carson, Kenneth Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] PD-L1 testing by immunohistochemistry in immuno-oncology
    Vranic, Semir
    Gatalica, Zoran
    BIOMOLECULES AND BIOMEDICINE, 2023, 23 (01): : 15 - 25
  • [4] The PD-1/PD-L1 Pathway: A Perspective on Comparative Immuno-Oncology
    Schoeniger, Sandra
    Jasani, Bharat
    ANIMALS, 2022, 12 (19):
  • [5] Will Testing for Tumor Mutational Burden Bring the Same Challenges as Testing for PD-L1?
    Gupta V.
    Ramirez M.C.
    Schauser L.
    Genetic Engineering and Biotechnology News, 2019, 39 (06): : 56 - 57
  • [6] PD-L1 in the palm of your hand: palmitoylation as a target for immuno-oncology
    von Knethen, Andreas
    Bruene, Bernhard
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2019, 4 (1)
  • [7] PD-L1 in the palm of your hand: palmitoylation as a target for immuno-oncology
    Andreas von Knethen
    Bernhard Brüne
    Signal Transduction and Targeted Therapy, 4
  • [8] Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
    Morrison, Carl
    Pabla, Sarabjot
    Conroy, Jeffrey M.
    Nesline, Mary K.
    Glenn, Sean T.
    Dressman, Devin
    Papanicolau-Sengos, Antonios
    Burgher, Blake
    Andreas, Jonathan
    Giamo, Vincent
    Qin, Moachun
    Wang, Yirong
    Lenzo, Felicia L.
    Omilian, Angela
    Bshara, Wiam
    Zibelman, Matthew
    Ghatalia, Pooja
    Dragnev, Konstantin
    Shirai, Keisuke
    Madden, Katherine G.
    Tafe, Laura J.
    Shah, Neel
    Kasuganti, Deepa
    de la Cruz-Merino, Luis
    Araujo, Isabel
    Saenger, Yvonne
    Bogardus, Margaret
    Villalona-Calero, Miguel
    Diaz, Zuanel
    Day, Roger
    Eisenberg, Marcia
    Anderson, Steven M.
    Puzanov, Igor
    Galluzzi, Lorenzo
    Gardner, Mark
    Ernstoff, Marc S.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [9] FREQUENT HIGH TUMOR MUTATIONAL BURDEN (TMB) AND PD-L1 EXPRESSION IN PRIMARY CNS LYMPHOMA (PCNSL)
    Sumrall, Ashley
    Phuphanich, Surasak
    Spetzler, David
    Gatalica, Zoran
    Xiu, Joanne
    Provenzano, Aaron
    Brenner, Andrew J.
    Subramaniam, Deepa
    Pandey, Majari
    Heimberger, Amy
    Kesari, Santosh
    Korn, W. Michael
    Mittal, Sandeep
    NEURO-ONCOLOGY, 2018, 20 : 240 - 241
  • [10] PD-1/PD-L1 Inhibitors for Immuno-oncology: From Antibodies to Small Molecules
    Geng, Qiaohong
    Jiao, Peifu
    Jin, Peng
    Su, Gaoxing
    Dong, Jinlong
    Yan, Bing
    CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (39) : 6033 - 6041
12345